205 related articles for article (PubMed ID: 36248860)
21. TCR repertoire, clonal dominance, and pulmonary trafficking of mycobacterium-specific CD4+ and CD8+ T effector cells in immunity against tuberculosis.
Du G; Chen CY; Shen Y; Qiu L; Huang D; Wang R; Chen ZW
J Immunol; 2010 Oct; 185(7):3940-7. PubMed ID: 20805423
[TBL] [Abstract][Full Text] [Related]
22. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
[TBL] [Abstract][Full Text] [Related]
23. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
24. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
[TBL] [Abstract][Full Text] [Related]
25. Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers.
Gertych A; Walts AE; Cheng K; Liu M; John J; Lester J; Karlan BY; Orsulic S
Cells; 2022 Nov; 11(23):. PubMed ID: 36497028
[TBL] [Abstract][Full Text] [Related]
26. Clonal distribution and intratumour heterogeneity of the B-cell repertoire in oesophageal squamous cell carcinoma.
Zhang C; Huang H; Miao Y; Xiong H; Lu Z
J Pathol; 2018 Nov; 246(3):323-330. PubMed ID: 30027584
[TBL] [Abstract][Full Text] [Related]
27. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
[TBL] [Abstract][Full Text] [Related]
28. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
29. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of the immune microenvironment in ovarian cancer patients.
Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D
Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640
[TBL] [Abstract][Full Text] [Related]
31. Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer.
Aquino-Acevedo AN; Knochenhauer H; Castillo-Ocampo Y; Ortiz-León M; Rivera-López YA; Morales-López C; Cruz-Robles ME; Hernández-Cordero ER; Russell S; Whitaker R; Bonilla-Claudio M; Chen DT; Dutil J; Gaillard SL; Yi JS; Previs RA; Armaiz-Pena GN
Brain Behav Immun Health; 2022 Dec; 26():100558. PubMed ID: 36439058
[TBL] [Abstract][Full Text] [Related]
32. Analysis of Gene Expression and TCR/B Cell Receptor Profiling of Immune Cells in Primary Sjögren's Syndrome by Single-Cell Sequencing.
Hou X; Hong X; Ou M; Meng S; Wang T; Liao S; He J; Yu H; Liu L; Yin L; Liu D; Tang D; Dai Y
J Immunol; 2022 Jul; 209(2):238-249. PubMed ID: 35705251
[TBL] [Abstract][Full Text] [Related]
33. TCR Repertoire Analysis Reveals Mobilization of Novel CD8
Aoki H; Ueha S; Shichino S; Ogiwara H; Hashimoto SI; Kakimi K; Ito S; Matsushima K
Front Immunol; 2018; 9():3185. PubMed ID: 30733724
[TBL] [Abstract][Full Text] [Related]
34. Select sequencing of clonally expanded CD8
Huang H; Sikora MJ; Islam S; Chowdhury RR; Chien YH; Scriba TJ; Davis MM; Steinmetz LM
Proc Natl Acad Sci U S A; 2019 Apr; 116(18):8995-9001. PubMed ID: 30992377
[TBL] [Abstract][Full Text] [Related]
35. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Färkkilä A; Gulhan DC; Casado J; Jacobson CA; Nguyen H; Kochupurakkal B; Maliga Z; Yapp C; Chen YA; Schapiro D; Zhou Y; Graham JR; Dezube BJ; Munster P; Santagata S; Garcia E; Rodig S; Lako A; Chowdhury D; Shapiro GI; Matulonis UA; Park PJ; Hautaniemi S; Sorger PK; Swisher EM; D'Andrea AD; Konstantinopoulos PA
Nat Commun; 2020 Mar; 11(1):1459. PubMed ID: 32193378
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.
Dong Y; Stephens C; Walpole C; Swedberg JE; Boyle GM; Parsons PG; McGuckin MA; Harris JM; Clements JA
PLoS One; 2013; 8(2):e57056. PubMed ID: 23451143
[TBL] [Abstract][Full Text] [Related]
37. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.
Feigenberg T; Clarke B; Virtanen C; Plotkin A; Letarte M; Rosen B; Bernardini MQ; Kollara A; Brown TJ; Murphy KJ
Biomed Res Int; 2014; 2014():367103. PubMed ID: 24982872
[TBL] [Abstract][Full Text] [Related]
38. Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer.
Qu H; Xia Y; Li X
Curr Gene Ther; 2020; 20(4):313-320. PubMed ID: 32851960
[TBL] [Abstract][Full Text] [Related]
39. Clonal expansion of bone marrow CD8
Feng Z; Fang Q; Kuang X; Liu X; Chen Y; Ma D; Wang J
Am J Cancer Res; 2020; 10(11):3973-3989. PubMed ID: 33294280
[TBL] [Abstract][Full Text] [Related]
40. Pathologic T-cell response in ischaemic failing hearts elucidated by T-cell receptor sequencing and phenotypic characterization.
Tang TT; Zhu YC; Dong NG; Zhang S; Cai J; Zhang LX; Han Y; Xia N; Nie SF; Zhang M; Lv BJ; Jiao J; Yang XP; Hu Y; Liao YH; Cheng X
Eur Heart J; 2019 Dec; 40(48):3924-3933. PubMed ID: 31365073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
